• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Renin release regulation during acute renin inhibition in normal volunteers.

作者信息

Ménard J, Guyene T T, Chatellier G, Kleinbloesem C H, Bernadet P

机构信息

INSERM U36, Paris, France.

出版信息

Hypertension. 1991 Sep;18(3):257-65. doi: 10.1161/01.hyp.18.3.257.

DOI:10.1161/01.hyp.18.3.257
PMID:1889841
Abstract

Blockade of the renin-angiotensin system by an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (Ang II) antagonist is accompanied by a reactive rise in renin release. This rise is generally attributed to interruption of the short feedback loop between Ang II and renin release. Similarly, after the administration of a renin inhibitor, the plasma concentrations of active and total renin are increased and plasma renin activity is suppressed. The aim of the present study was to investigate if a fall in the plasma Ang II level is the unique determinant of the rise in the active renin (AR) level that follows renin inhibition. Six normal male volunteers participated in three successive 240-minute experiments at weekly intervals according to a single-blind randomized Latin square design. For experiment 1, Ang II was infused at 2 ng/kg/min from 0 to 60 minutes and at 4 ng/kg/min from 60 to 120 minutes. For experiment 2, 0.3 mg/kg of the new potent renin inhibitor Ro 42-5892 was injected at 30 minutes followed by infusion at 0.1 mg/kg/hr from 30 to 240 minutes. For experiment 3, Ang II and Ro 42-5892 were administered simultaneously at the same doses as described above. The mean +/- SEM Ang II concentration increased from 10.2 +/- 1.6 to 33.7 +/- 11.2 pg/ml after infusion of exogenous peptide. It decreased from 9.5 +/- 0.9 to 1.4 +/- 0.3 pg/ml after the injection of Ro 42-5892 and increased from 15.6 +/- 2.9 to 37.1 +/- 11.8 pg/ml after the simultaneous infusion of both compounds.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Renin release regulation during acute renin inhibition in normal volunteers.
Hypertension. 1991 Sep;18(3):257-65. doi: 10.1161/01.hyp.18.3.257.
2
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.血管紧张素转换酶抑制与血管紧张素II拮抗联合应用对钠缺乏正常血压者血压及肾素释放的相加作用
Circulation. 1995 Aug 15;92(4):825-34. doi: 10.1161/01.cir.92.4.825.
3
Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans.肾素抑制过程中肾素反应的影响:正常人体内口服Ro 42 - 5892的情况。
J Cardiovasc Pharmacol. 1991 Sep;18(3):299-307. doi: 10.1097/00005344-199109000-00001.
4
Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.原发性高血压患者中肾素抑制剂Ro 42 - 5892与血管紧张素转换酶抑制剂依那普利对血压及血管紧张素反应的比较。
J Hypertens. 1993 Aug;11(8):831-8. doi: 10.1097/00004872-199308000-00010.
5
Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.血管紧张素转换酶基因多态性对血压正常者的循环肾素-血管紧张素-醛固酮系统或血压无影响。
Circulation. 1995 Jun 15;91(12):2933-42. doi: 10.1161/01.cir.91.12.2933.
6
Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.
J Cardiovasc Pharmacol. 1990 Feb;15(2):276-82. doi: 10.1097/00005344-199002000-00015.
7
Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men.
J Cardiovasc Pharmacol. 1992 Dec;20(6):875-80. doi: 10.1097/00005344-199212000-00005.
8
Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats.清醒大鼠对肾素或血管紧张素 II 进行 14 天输注的血流动力学和激素反应相同。
J Hypertens. 1998 Sep;16(9):1285-98. doi: 10.1097/00004872-199816090-00010.
9
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.口服活性肾素抑制剂阿利吉仑(SPP100)对人体血管紧张素II的抑制作用:与依那普利的比较。
Hypertension. 2002 Jan;39(1):E1-8. doi: 10.1161/hy0102.102293.
10
Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys.慢性输注肾素抑制剂A-64662对钠缺乏猴子的影响。
Hypertension. 1989 Mar;13(3):262-72. doi: 10.1161/01.hyp.13.3.262.

引用本文的文献

1
Molecular basis of a redox switch: molecular dynamics simulations and surface plasmon resonance provide insight into reduced and oxidised angiotensinogen.氧化还原开关的分子基础:分子动力学模拟和表面等离子体共振为还原型和氧化型血管紧张素原提供了深入了解。
Biochem J. 2021 Sep 17;478(17):3319-3330. doi: 10.1042/BCJ20210476.
2
Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration.血管紧张素转换酶调节细胞增殖和迁移。
PLoS One. 2016 Dec 19;11(12):e0165371. doi: 10.1371/journal.pone.0165371. eCollection 2016.
3
Dual blockade of the renin-angiotensin system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
使用血管紧张素转换酶(ACE)抑制剂和血管紧张素受体阻滞剂(ARB)对肾素-血管紧张素系统进行双重阻断。
Br J Clin Pharmacol. 2011 Mar;71(3):313-5. doi: 10.1111/j.1365-2125.2011.03918.x.
4
Dual renin-angiotensin system blockade in the ONTARGET study: clinically relevant risk for the kidney?ONTARGET 研究中的双重肾素-血管紧张素系统阻断:对肾脏有临床相关风险吗?
Curr Hypertens Rep. 2009 Oct;11(5):375-81. doi: 10.1007/s11906-009-0062-1.
5
Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients.口服活性肾素抑制剂瑞米吉仑(Ro 42-5892)在高血压患者中的多剂量药代动力学及浓度-效应关系
Br J Clin Pharmacol. 1993 Dec;36(6):547-54. doi: 10.1111/j.1365-2125.1993.tb00413.x.
6
Angiotensin receptor blockers in diabetic nephropathy.血管紧张素受体阻滞剂在糖尿病肾病中的应用
Curr Diab Rep. 2001 Dec;1(3):267-74. doi: 10.1007/s11892-001-0045-3.
7
Clinical pharmacokinetics and efficacy of renin inhibitors.肾素抑制剂的临床药代动力学与疗效
Clin Pharmacokinet. 1995 Jul;29(1):6-14. doi: 10.2165/00003088-199529010-00002.